The FDA cleared an investigational new drug application for AVZO-1418/DB-1418, and a phase 1/2 trial in advanced solid tumors ...

ProteinQure Inc., a biotechnology company pioneering computational peptide therapeutics, announced today the close of an $11 million Series A financing round. The proceeds will support the initiation ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced multiple clinical research results to be presented at the 2025 American Society of Clinical ...

AbbVie Inc ABBV stock is trending on Tuesday after the U.S. drug giant announced that key data from its broad oncology ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophoblast cell-surface antigen 2 (TROP2)-directed ...

BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Lt ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...

Discovered and developed by Lilly researchers, Verzenio was first approved in 2017 and is currently authorized for use in more than 90 counties around the world. For full details on indicated uses of ...

The agreement includes an upfront payment of $20 million to Munich-based Tubulis for opt-in rights to the ADC, which will carry a topoisomerase I inhibitor payload and is directed at an ...